| Name | Title | Contact Details |
|---|
American Clinical Solutions is a leading provider of urine drug confirmation services, offering accurate testing for both prescription and illicit narcotics using the most advanced equipment available. Medical facilities and other healthcare providers rely on American Clinical to help ensure patient safety and maximize the benefits of prescription medicine use. ACS employs a unique, proprietary testing method with enhanced detection ability and improved accuracy which means physicians and other health care providers can prescribe with confidence. In addition to detecting improper use of prescribed and illicit drugs, ACS testing method helps healthcare providers monitor the efficacy of prescription regimens and alter the dosing scheme in response to changes in patient health status, behavior or other variables, helping patients achieve better outcomes while providing an overall greater level of safety. ACS techniques and technology were developed to meet or exceed the latest testing standards. Input from our physician colleagues provides invaluable guidance to help us refine our approach to ensure we continue to provide the best, most accurate testing results and reporting services available.
Subconscious Training Corporation is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Helping all patients feel known and heard when they need it most. Docent Health`s mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.
MediSystem Technologies Inc. is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.